Molecular Partners AG
SIX:MOLN
Intrinsic Value
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. [ Read More ]
The intrinsic value of one
MOLN
stock under the Base Case scenario is
6.46
CHF.
Compared to the current market price of 3.2 CHF,
Molecular Partners AG
is
Undervalued by 50%.
Molecular Partners AG's market capitalization is 105.1m CHF.
MOLN stock price is 3.2 CHF.
MOLN stock price (3.2 CHF) is 50% less than its Intrinsic Value (6.46 CHF).
MOLN. Open DCF Valuation
MOLN has upside potential of 187% compared to the average analyst price target.
Open Wall St Estimates
MOLN's Revenue has been falling by 9% per year for the last 3 years.
MOLN has positive Gross Profit for the last twelve months.
MOLN's Revenue has dropped by 96% over the past 12 months.
MOLN's ROE (Return on Equity) has significantly increased in the last 3 years from -78% to -30%, and is approaching profitability.
MOLN's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -755% to -579%, and is approaching profitability.
MOLN has negative three-year average ROE (Return on Equity): -2%. The company is not efficient at transforming stockholders' equity into net income.
MOLN's Revenue is forecast to grow at a rate of 43% per year over the next 3 years.
MOLN has negative Operating Income for the last twelve months.
MOLN has negative Net Income for the last twelve months.
MOLN's ROE (Return on Equity) for the past 12 months is negative and is equal to -30%.
MOLN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -579%.
MOLN has negative Free Cash Flow for the last twelve months.
MOLN's D/E (Debt to Equity) is very low and is equal to 0.01.
MOLN has very high three-year average ROIC (Return on Invested Capital): 81%. The company is very efficient at using invested capital to generate operating income.
MOLN's short-term assets (192m CHF) exceed its short-term liabilties (14m CHF).
MOLN's long-term assets (198m CHF) exceed its long-term liabilties (22m CHF).
MOLN has negative Net Debt. This means that the company has more cash and short-term investments (187m CHF) than debt (2m CHF).
MOLN's Altman Z-Score is very low and is equal to 0.71.
MOLN doesn't generate enough operating income (-61m CHF) to safely cover interest payments on its debt (34k CHF).
Valuation Backtest
Molecular Partners AG
Run backtest to discover the historical profit from buying and selling
MOLN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Molecular Partners AG
Balance Sheet Decomposition
Molecular Partners AG
| Current Assets | 192.5m |
| Cash & Short-Term Investments | 186.9m |
| Receivables | 2m |
| Other Current Assets | 3.6m |
| Non-Current Assets | 5.9m |
| PP&E | 5.7m |
| Intangibles | 212k |
| Current Liabilities | 14.4m |
| Accounts Payable | 1.3m |
| Accrued Liabilities | 7.5m |
| Other Current Liabilities | 5.5m |
| Non-Current Liabilities | 7.5m |
| Long-Term Debt | 2.4m |
| Other Non-Current Liabilities | 5.1m |
Earnings Waterfall
Molecular Partners AG
|
Revenue
|
7m
CHF
|
|
Cost of Revenue
|
-10k
CHF
|
|
Gross Profit
|
7m
CHF
|
|
Operating Expenses
|
-68.1m
CHF
|
|
Operating Income
|
-61.1m
CHF
|
|
Other Expenses
|
-876k
CHF
|
|
Net Income
|
-62m
CHF
|
Free Cash Flow Analysis
Molecular Partners AG
MOLN Profitability Score
Profitability Due Diligence
Molecular Partners AG's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Molecular Partners AG's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
MOLN Solvency Score
Solvency Due Diligence
Molecular Partners AG's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Molecular Partners AG's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOLN Price Targets Summary
Molecular Partners AG
According to Wall Street analysts, the average 1-year price target for
MOLN
is 9.18 CHF
with a low forecast of 3.03 CHF and a high forecast of 15.75 CHF.
Shareholder Return
MOLN Price
Molecular Partners AG
| Average Annual Return | -15.73% |
| Standard Deviation of Annual Returns | 37.09% |
| Max Drawdown | -89% |
| Market Capitalization | 105.1m CHF |
| Shares Outstanding | 36 056 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Molecular Partners AG
Country
Industry
Market Cap
Dividend Yield
Description
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Contact
IPO
Employees
Officers
The intrinsic value of one
MOLN
stock under the Base Case scenario is
6.46
CHF.
Compared to the current market price of 3.2 CHF,
Molecular Partners AG
is
Undervalued by 50%.
You don't have any saved screeners yet
